Please login to the form below

Not currently logged in
Email:
Password:

Key pharma financial results for 2009

Several pharma companies have posted financial results for Q4 2009, indicating a mainly positive result in sales performance for the full year

Several pharmaceutical companies have posted financial results for Q4 2009, indicating a mainly positive result in sales performance for the full year in comparison with 2008.

Despite news of a further 8,000 job cuts, anglo-Swedish firm AstraZeneca (AZ) saw revenue for the full year increase by 7 per cent at constant exchange rates to $32.8bn, in what it describes as a 'strong financial performance in 2009'. AZ's Q4 results also met guidance set at Q3 by the company, increasing by 4 per cent.

Three per cent of the increase was down to sales of Toprol-XL and Novel Influenza A (H1N1) vaccine in the US, while there was good news in emerging markets which saw an increase in revenue of 12 per cent, accounting for 13 per cent of total company revenue for the full year.

Johnson & Johnson announced overall Q4 sales of $16.6bn - an increase of 9 per cent from Q4 2008, though sales for the full year decreased by 2.9 per cent to $61.9bn from 2008.

Worldwide pharmaceutical sales for the US healthcare giant were $22.5bn for the full-year 2009, representing a decrease of 8.3% versus the prior year with an operational decline of 6.1% and a negative impact from currency of 2.2%.

Novartis, who recently announced the appointment of Joe Jimenez as new CEO, saw 'record results' in 2009 as net sales rose 7 per cent to $44.3bn, a total which included over 100 million influenza A (H1N1) pandemic vaccine doses. There was good news for Q4 results too, with an increase of 28 per cent from $10.1bn to $12.9bn.

Abbott also saw sales increase, with Q4 2009 showing a rise of 10.6 per cent in worldwide sales from Q4 2008 to total $8.8bn. There was also a rise in results for the full year, with total worldwide sales increasing by 4.2 per cent to $30.8bn.

There were increases in sales at Bristol-Myers Squibb (BMS) too, as Q4 results increased by 11 per cent to $5bn. Growth for the full year was slightly lower at 6 per cent, with final net sales for 2009 of $18.8bn.

GlaxoSmithKline (GSK), who are expected to announce the loss of 3,000 jobs, has said it will reveal its end of year finances on February 4. Merck will follow with their results on February 16.

Pfizer is still to disclose its 2009 finances – a year which saw it close the acquisition of Wyeth – though the company provided an update on its pipeline which, according to a statement "includes 133 programmes from phase I through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development."

Roche and sanofi-aventis are yet to publish details of their end of year results.

2nd February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics